Insider Transactions in Q1 2025 at Kura Oncology, Inc. (KURA)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 28
2025
|
Thomas James Doyle SVP, Finance & Accounting |
SELL
Open market or private sale
|
Direct |
4,949
-1.35%
|
$34,643
$7.87 P/Share
|
|
Jan 28
2025
|
Brian T. Powl Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,583
-2.58%
|
$11,081
$7.87 P/Share
|
|
Jan 28
2025
|
Francis Burrows Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,166
-4.85%
|
$15,162
$7.87 P/Share
|
|
Jan 28
2025
|
Kathleen Ford Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,817
-7.84%
|
$12,719
$7.87 P/Share
|
|
Jan 28
2025
|
Teresa Brophy Bair Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
7,281
-3.2%
|
$50,967
$7.87 P/Share
|
|
Jan 28
2025
|
Mollie Leoni Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,963
-1.36%
|
$34,741
$7.87 P/Share
|
|
Jan 02
2025
|
Mollie Leoni Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
46,250
+33.16%
|
-
|
|
Jan 02
2025
|
Brian T. Powl Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
46,250
+43.02%
|
-
|
|
Jan 02
2025
|
Teresa Brophy Bair Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
46,250
+28.64%
|
-
|
|
Jan 02
2025
|
Thomas James Doyle SVP, Finance & Accounting |
BUY
Grant, award, or other acquisition
|
Direct |
42,500
+20.7%
|
-
|